You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 7,364,736

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,364,736

Title:	Antibodies to OPGL
Abstract:	Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
Inventor(s):	Boyle; William J. (Thousand Oaks, CA), Martin; Francis H. (Newbury Park, CA), Corvalan; Jose R. (Foster City, CA), Davis; C. Geoffrey (Burlingame, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA)
Application Number:	10/180,648
Patent Claims:	1. An isolated antibody comprising: a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2; and b) a light chain comprising the amino acid sequence of SEQ ID NO: 4. 2. An isolated antibody consisting of: a) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2; and b) a light chain consisting of the amino acid sequence of SEQ ID NO: 4. 3. An isolated antibody comprising: a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 13; and b) a light chain comprising the amino acid sequence of SEQ ID NO: 14. 4. The antibody of claim 3, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody. 5. The antibody of claim 4, which is a single-chain Fv antibody. 6. The antibody of claim 3, which is a Fab antibody. 7. The antibody of claim 3, which is a Fab' antibody. 8. The antibody of claim 3, which is a F(ab').sub.2 antibody. 9. The antibody of claim 3, which is fully human. 10. The antibody of claim 3, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR). 11. An isolated antibody comprising: a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13; and b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14. 12. The antibody of claim 11, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody. 13. The antibody of claim 12, which is a single-chain Fv antibody. 14. The antibody of claim 11, which is a Fab antibody. 15. The antibody of claim 11, which is a Fab' antibody. 16. The antibody of claim 11, which is a F(ab').sub.2 antibody. 17. The antibody of claim 11, which is fully human. 18. The antibody of claim 11, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR). 19. A pharmaceutical composition comprising the antibody of any one of claims 1, 2, 3, and 11. 20. The pharmaceutical composition of claim 19, wherein the composition comprises an acetate buffer. 21. The pharmaceutical composition of claim 19, wherein the composition comprises polysorbate. 22. The pharmaceutical composition of claim 19, wherein the composition comprises sorbitol. 23. The pharmaceutical composition of claim 19, wherein the composition comprises acetate and sorbitol. 24. The pharmaceutical composition of claim 19, wherein the composition is contained in a prefilled syringe. 25. The pharmaceutical composition of claim 19, wherein the composition is in unit dose form.

Details for Patent 7,364,736

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	⤷ Subscribe	2021-06-26
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	⤷ Subscribe	2021-06-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,364,736

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	200400521	⤷ Subscribe
Yugoslavia	103003	⤷ Subscribe
World Intellectual Property Organization (WIPO)	03002713	⤷ Subscribe
United States of America	8409578	⤷ Subscribe
United States of America	8058418	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.